Jonathan S. Berek
Academic Appointments
- Professor, Obstetrics & Gynecology - Oncology
Contact Information
-
Clinical Offices
Stanford Comprehensive Cancer Center 875 Blake Wilbur Dr Clinic C Gynecologic Oncology Clinic Stanford, CA 94305 Tel Work (650) 498-6000Practices at Stanford Hospital and Clinics and Lucile Packard Children's Hospital
- Academic Offices
Personal Information Email Tel (650) 723-5533Administrative Contact Kerry Garcia Assistant to the Chair Email Tel Work 650-723-5533Not for medical emergencies or patient use
Professional Snapshot
Clinical Focus
- Cancer> Gynecologic Cancer
- Gynecologic Oncology
- Gynecologic Cancers - Gynecologic Oncology
- Ovarian Cancer
- Uterine Cancer
Administrative Appointments
- Chair, Department of Obstetrics and Gynecology, Stanford University School of Medicine (2005 - present)
- Director, Women's Cancer Program, Stanford Cancer Center (2008 - present)
Professional Education
| Board Certification: | Gynecologic Oncology, American Board of Obstetrics and Gynecology (1983) |
| Fellowship: | UCLA - School of Medicine, CA (1981) |
| Residency: | Harvard Medical School, Brigham & Women's Hospital, MA (1979) |
| Internship: | Harvard Medical School, Brigham & Women's Hospital, MA (1976) |
| Board Certification: | Obstetrics and Gynecology, American Board of Obstetrics and Gynecology (1982) |
Postdoctoral Advisees
Community & International Work
Industry Relationships
Stanford is committed to ethical and transparent interactions with our industry partners. It is our policy to disclose payments of $5,000 or more, equity valued at $5,000 or more in a publicly traded company, or any equity in a privately held company, to physicians and scientists employed by Stanford University from companies or other commercial entities with which they interact as part of their professional activities. View Full Information
| Consulting: | Telik, Inc. |
Scientific Focus
Clinical Trials
- A Study of Carboplatin and Gemcitabine Plus Bevacizumab in Patients With Ovary, Peritoneal, or Fallopian Tube Carcinoma (OCEANS) Recruiting
- Combination Study Of SB-485232 (Interleukin 18) And Doxil For Advanced Stage Epithelial Ovarian Cancer Recruiting
- Study of the Trifunctional Antibody Catumaxomab to Treat Recurrent Symptomatic Malignant Ascites Recruiting
- AZD6244 in Treating Woman With Recurrent Low-Grade Ovarian Cancer Recruiting
- Bevacizumab and Intravenous or Intraperitoneal Chemotherapy in Treating Patients With Stage II, Stage III, or Stage IV Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer Recruiting
Publications
- Oregovomab maintenance monoimmunotherapy does not improve outcomes in advanced ovarian cancer. J Clin Oncol. 2009; (3): 418-25
- Ovarian conservation at the time of hysterectomy and long-term health outcomes in the nurses' health study. Obstet Gynecol. 2009; (5): 1027-37
- Survival after second-line intraperitoneal therapy for the treatment of epithelial ovarian cancer: the Gynecologic Oncology Group experience. Int J Gynecol Cancer. 2009; (2): 223-9
- Lymph node-positive stage IIIC ovarian cancer: a separate entity? Int J Gynecol Cancer. 2009: S18-20
- CA125 velocity at relapse is a highly significant predictor of survival post relapse: results of a 5-year follow-up survey to a randomized placebo-controlled study of maintenance oregovomab immunotherapy in advanced ovarian cancer. J Immunother. 2008 Feb-Mar; (2): 207-14
Help